Effects of Acute Grape Seed Extract Supplementation on Muscle Metaboreflex in Healthy Young Individuals

Dietary Supplementation Clinical Trial

Official title:

Effects of Acute Grape Seed Extract Supplementation on Muscle Metaboreflex in Healthy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05945771
• Other study ID #: 107-2122-EXP
• Status: Completed
• Phase: N/A
• Start date: May 1, 2022
• Est. completion date: August 31, 2022

Study information

• Verified date: July 2023
• Source: California Baptist University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study was to determine whether grape seed extract (GSE) supplementation could reduce the blood pressure (BP) in response to static exercise and post exercise muscular ischemia (PEMI) in normotensive young adults. In 12 healthy subjects (7 male and 5 female, 24.6±3.4 yr), we compared acute effect of both GSE (600 mg) and placebo (PL: 600 mg) on changes from rest in systolic BP (SBP), diastolic BP (DBP), mean arterial pressure (MAP), heart rate (HR), stroke volume (SV), cardiac output (CO), and total peripheral resistance (TPR) during static exercise (SE) and PEMI. Subjects completed 2 min of SE at 30% of maximal voluntary contraction (MVC) followed by 2 min of PEMI.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: August 31, 2022
• Est. primary completion date: August 31, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 30 Years

Eligibility

Inclusion Criteria:

• Healthy volunteers (SBP < 120 mmHg, DBP < 80 mmHg)

Exclusion Criteria:

• cardiovascular and/or pulmonary disease,
• musculoskeletal disorders
• medications that prevent the safe completion of the exercise protocol

Related Conditions & MeSH terms

• Dietary Supplementation

Intervention

Dietary Supplement:
• Grape seed extract
Acute effect of dietary supplementation with GSE on hemodynamic responses during static exercise and muscle metaboreflex and during cycling exercise.

Locations

Country	Name	City	State
United States	California Baptist University	Riverside	California

Sponsors (1)

Lead Sponsor	Collaborator
California Baptist University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Systolic blood pressure (mmHg) by sphygmomanometer	Measured from the brachial artery	24 hours
Primary	Diastolic blood pressure (mmHg) by sphygmomanometer	Measured from the brachial artery	24 hours
Primary	Mean arterial pressure (mmHg)	calculated (MAP = (SBP-DBP)/3 + DBP	24 hours
Primary	Heart rate (bpm)	measured using Physio Flow (non-invasive device)	24 hours
Primary	Stroke volume (ml)	measured using Physio Flow (non-invasive device)	24 hours
Primary	Cardiac output (l/min)	calculated: HR (bpm) x SV (ml)	24 hours
Primary	Total peripheral resistance (mmHg/l/min)	calculated: MAP (mmHg) / CO (l/min)	24 hours